Equities

Haemonetics Corp

Haemonetics Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)83.05
  • Today's Change0.34 / 0.41%
  • Shares traded217.49k
  • 1 Year change+58.43%
  • Beta0.3661
Data delayed at least 15 minutes, as of Nov 29 2022 20:36 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Haemonetics Corporation is a healthcare company. The Company provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. It markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.

  • Revenue in USD (TTM)1.08bn
  • Net income in USD86.05m
  • Incorporated1985
  • Employees2.82k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Patterson Companies, Inc.6.41bn193.80m2.76bn7.70k14.412.6810.080.43081.971.9765.1510.592.336.1817.23832,181.106.98-0.182811.32-0.269120.6521.183.00-0.09680.7965--0.3816--9.933.0530.283.18-4.021.20
LivaNova PLC1.02bn-96.47m2.80bn3.00k--2.45--2.76-1.81-1.8118.9121.430.46062.415.74338,998.30-4.37-5.98-5.56-7.3470.9265.94-9.48-14.042.530.81950.3201--10.821.4260.90---7.86--
STAAR Surgical Company279.35m37.82m2.84bn692.0076.918.8767.8110.170.76630.76635.666.640.77673.335.74403,682.1010.525.8312.067.0878.2574.4413.546.986.1110.260.00130.0041.0022.83314.36--33.61--
Adapthealth Corp2.89bn86.96m2.89bn10.70k33.691.336.810.99870.63650.636515.5216.080.554721.188.20270,319.401.88--2.08--17.53--3.39--1.082.750.504--132.35--187.73------
Inmode Ltd431.24m176.50m2.94bn362.0017.145.7916.616.822.062.065.056.120.84012.5217.021,191,271.0034.3837.6438.5945.4883.9285.2640.9338.019.12828.050.000.0073.4972.99119.87245.3137.94--
Axonics Inc240.92m-75.53m3.17bn517.00--5.77--13.18-1.66-1.665.2811.110.40371.117.58465,994.20-12.66-25.46-13.67-28.7070.6062.16-31.35-86.626.44-52.960.00--61.64---45.80--50.57--
ICU Medical Inc2.04bn-38.83m3.73bn8.50k--1.8522.831.82-1.57-1.5787.5083.940.64953.0412.42240,295.10-1.235.01-1.385.7631.8436.98-1.905.991.171.020.45150.003.5628.2518.7210.3327.02--
Premier Inc1.38bn186.58m3.90bn2.60k21.311.7312.152.831.541.5411.4619.040.39553.463.48531,395.005.4413.147.0516.3263.3362.6313.7527.380.734--0.189310.88-16.756.091.9328.364.14--
Inari Medical Inc358.92m-22.36m3.96bn800.00--9.53--11.04-0.4207-0.42076.917.750.921.617.72448,647.50-5.73---6.31--88.95---6.23--9.00--0.00--98.31---28.64------
Merit Medical Systems Inc1.14bn61.73m3.99bn6.45k65.463.6727.753.521.071.0719.7319.130.69362.747.41176,242.303.771.604.331.8045.1943.925.432.561.1918.640.1660.0011.5012.22592.2719.22-2.57--
Haemonetics Corporation1.08bn86.05m4.19bn2.82k49.515.7423.113.861.671.6721.0514.410.59111.766.93384,159.504.694.595.525.7853.0248.097.946.941.7610.730.52870.0014.102.31-45.42--4.86--
Lantheus Holdings Inc801.46m107.04m4.19bn612.0040.896.5726.985.231.491.4911.469.270.82479.576.131,309,570.0011.010.959613.131.0958.9547.4613.361.431.9829.330.20790.0025.287.09-429.05--10.41--
Stevanato Group SpA955.30m143.83m4.43bn4.65k27.613.9921.214.640.54330.54333.613.760.6133.443.59205,351.809.24--12.41--31.91--15.07--1.51--0.1969--27.47--71.08------
MSA Safety Inc1.49bn69.06m5.41bn4.80k79.026.4543.273.621.751.7537.9721.490.64352.796.38311,451.302.975.173.496.1944.0344.744.626.801.475.360.417968.393.854.02-82.84-25.3913.995.96
Novanta Inc841.49m72.54m5.50bn2.70k76.2610.1543.576.542.022.0223.4615.190.69613.366.56311,663.006.006.147.007.2843.5942.148.628.051.559.880.45260.0019.6712.9313.0518.009.93--
Data as of Nov 29 2022. Currency figures normalised to Haemonetics Corp's reporting currency: US Dollar USD

Institutional shareholders

61.98%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (Global Investors)as of 30 Sep 20226.29m12.25%
Wellington Management Co. LLPas of 30 Sep 20225.37m10.46%
The Vanguard Group, Inc.as of 30 Sep 20225.06m9.86%
BlackRock Fund Advisorsas of 30 Sep 20225.05m9.83%
Neuberger Berman Investment Advisers LLCas of 30 Sep 20223.89m7.59%
SSgA Funds Management, Inc.as of 30 Sep 20221.70m3.31%
Franklin Advisers, Inc.as of 30 Sep 20221.34m2.61%
Fisher Asset Management LLCas of 30 Sep 20221.25m2.43%
Schroder Investment Management North America, Inc.as of 30 Sep 2022983.00k1.92%
Geode Capital Management LLCas of 30 Sep 2022885.52k1.73%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.